Cargando…

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

BACKGROUND: Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since chemoradiotherapy combined with immune checkpoint inhibitors has been reported to have synergic effects. This study aims to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Jiale, Zhang, Xiao, Yang, Zhengyang, Zhang, Jie, Bai, Zhigang, Deng, Wei, Chen, Guangyong, Xu, Rui, Wei, Qi, Liu, Yishan, Han, Jiagang, Li, Ang, Liu, Gang, Sun, Yi, Kong, Dalu, Yao, Hongwei, Zhang, Zhongtao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933500/ https://www.ncbi.nlm.nih.gov/pubmed/36816939 http://dx.doi.org/10.3389/fonc.2023.1057947

Ejemplares similares

Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)
por: Yang, Zhengyang, et al.
Publicado: (2022)

Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer
por: Yang, Zhengyang, et al.
Publicado: (2022)

Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer
por: Zhang, Jin-Liang, et al.
Publicado: (2017)

Opportunities and Challenges of Nanoparticles in Digestive Tumours as Anti-Angiogenic Therapies
por: Yang, Zhengyang, et al.
Publicado: (2022)

Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial
por: Fan, Wen-Hua, et al.
Publicado: (2015)

Long-course chemoradiation plus concurrent/sequential PD-1 blockade as neoadjuvant treatment for MMR-status-unscreened locally advanced rectal cancer: protocol of a multicentre, phase 2, randomised controlled trial (the POLAR-STAR trial)
por: Pang, Kai, et al.
Publicado: (2023)

Prognostic nutrition index predicts short-term surgical complications in patients with rectal cancer after laparoscopic surgery
por: Xu, Fengming, et al.
Publicado: (2022)

Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis
por: Zhang, Xiao, et al.
Publicado: (2022)

Durable response of tislelizumab plus cisplatin, nab-paclitaxel followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A case report
por: Tang, Haifeng, et al.
Publicado: (2023)

Abdomen anatomic characteristics on CT scans as predictive markers for short-term complications following radical resection of colorectal cancer
por: Zhang, Xiao, et al.
Publicado: (2022)

Concurrent chemoradiotherapy plus anlotinib vs. concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: An interim analysis of a multicenter randomized controlled trial
por: Chen, Kequan, et al.
Publicado: (2023)

Current Progress and Outlook of Nano-Based Hydrogel Dressings for Wound Healing
por: Zhang, Xiao, et al.
Publicado: (2022)

Neoadjuvant chemoradiotherapy plus tislelizumab followed by surgery for esophageal carcinoma (CRISEC study): the protocol of a prospective, single-arm, phase II trial
por: Yang, Jinsong, et al.
Publicado: (2023)

Utility of RGNEF in the Prediction of Clinical Prognosis in Patients with Rectal Cancer Receiving Preoperative Concurrent Chemoradiotherapy
por: Chen, Chih-I., et al.
Publicado: (2021)

Prognosis comparison between wait and watch and surgical strategy on rectal cancer patients after treatment with neoadjuvant chemoradiotherapy: a meta-analysis
por: Pang, Kai, et al.
Publicado: (2019)

Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer
por: Lee, Hong Seok, et al.
Publicado: (2016)

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma
por: Xu, Guoqiang, et al.
Publicado: (2021)

Overexpression of Transcobalamin 1 is an Independent Negative Prognosticator in Rectal Cancers Receiving Concurrent Chemoradiotherapy
por: Lee, Yi-Ying, et al.
Publicado: (2017)

Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis
por: Lee, Jeong Won, et al.
Publicado: (2013)

Analysis of influencing factors of no/low response to preoperative concurrent chemoradiotherapy in locally advanced rectal cancer
por: Wu, Fengpeng, et al.
Publicado: (2020)

Association between dose-volume parameters and acute bone marrow suppression in rectal cancer patients treated with concurrent chemoradiotherapy
por: Li, Nan, et al.
Publicado: (2017)

Prospective, longitudinal analysis of the gut microbiome in patients with locally advanced rectal cancer predicts response to neoadjuvant concurrent chemoradiotherapy
por: Sun, Yi, et al.
Publicado: (2023)

Interim analysis of postoperative chemoradiotherapy with capecitabine and oxaliplatin versus capecitabine alone for pathological stage II and III rectal cancer: a randomized multicenter phase III trial
por: Feng, Yan-Ru, et al.
Publicado: (2016)

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study
por: Song, Yuqin, et al.
Publicado: (2019)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

The taTME learning curve for mid-low rectal cancer: a single-center experience in China
por: Xu, Fengming, et al.
Publicado: (2022)

Combining chemotherapy and tislelizumab with preoperative split-course hypofraction radiotherapy for locally advanced rectal cancer: study protocol of a prospective, single-arm, phase II trial
por: Zheng, Rong, et al.
Publicado: (2023)

Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer: Treatment Outcomes and Analysis of Prognostic Factors
por: Kong, Moonkyoo, et al.
Publicado: (2012)

Chemoradiotherapy and concurrent radiofrequency thermal therapy to treat primary rectal cancer and prediction of treatment responses
por: Shoji, Hisanori, et al.
Publicado: (2017)

HIF-1α Expression Increases Preoperative Concurrent Chemoradiotherapy Resistance in Hyperglycemic Rectal Cancer
por: Huang, Yi-Jung, et al.
Publicado: (2022)

Over-Expression of CHD4 Is an Independent Biomarker of Poor Prognosis in Patients with Rectal Cancers Receiving Concurrent Chemoradiotherapy
por: Wang, Hui-Ching, et al.
Publicado: (2019)

The efficacy and safety of concurrent chemoradiotherapy with induction chemotherapy vs. concurrent chemoradiotherapy alone for locally advanced nasopharyngeal carcinoma: a systematic-review and meta-analysis
por: Liu, Yun, et al.
Publicado: (2022)

Upregulated Ubiquitin D is a Favorable Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy
por: Chou, Chia-Lin, et al.
Publicado: (2022)

Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients
por: Chen, Tzu-Ju, et al.
Publicado: (2022)

Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone
por: Chen, Yu-Pei, et al.
Publicado: (2015)

The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer
por: Kim, Ka-Rham, et al.
Publicado: (2017)

Volumetric imaging parameters are significant for predicting the pathological complete response of preoperative concurrent chemoradiotherapy in local advanced rectal cancer
por: Wu, Fengpeng, et al.
Publicado: (2019)

Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer
por: Klautke, G, et al.
Publicado: (2005)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
por: Chen, Wanghua, et al.
Publicado: (2018)

Neoadjuvant therapy of metformin is associated with good tumor response after preoperative concurrent chemoradiotherapy for rectal cancer
por: Han, Jeonghee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k6tukeo6ra6r1ks0rg8a24pqg7